Skip to main content
SpringerLink
Log in

Effizienz von Flupentixol bei schizophrenen Erkrankungen

  • Conference paper
Flupentixol — Typisches oder atypisches Wirkspektrum?

Zusammenfassung

Aufgrund seiner Eigenschaften kommt Flupentixol in der Akut- und Langzeittherapie schizophrener Erkrankungen seit über 30 Jahren zum Einsatz. Ziel des vorliegenden Artikels ist die Darstellung der Ergebnisse klinischer Studien zur Verträglichkeit, dem Wirkspektrum und der Erhaltungsdosis. Schlußfolgernd soll die Effizienz von Flupentixol beurteilt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Agrup AL, Bengtsson A, Erlandsson K, Gottfries CG, Witzell OG (1974) Flupenthixol decanoate — controlled investigation concerning dosage. Acta Psychiatr Scand Suppl 255:7–14

    Google Scholar 

  • Angst J, Stassen HH, Woggon B (1989) Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacology 99:41–46

    Article  Google Scholar 

  • Anonymous (1987) The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group. Br J Psychiatry 150:334–338

    Article  Google Scholar 

  • Arihan AG, Göktürk S (1997) Efficacy and tolerability of flupenthixol in the treatment of psychiatric illness. Acta Pharmaceutica Turcica 39, 1:7–10

    CAS  Google Scholar 

  • Astrup C, Grimgard A, Hebnes K, Kruse JA, Lid M (1974) A study of flupenthixol decanoate and pipotiazine undecylenate in schizophrenics. Acta Psychiatr Scand 50:481–491

    Article  PubMed  CAS  Google Scholar 

  • Balant GA, Eisele R, Aeschlimann JM, Balant LP, Garrone G (1985) Plasma flupentixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit 7: 411–414

    Article  PubMed  Google Scholar 

  • Benkert O, Hippius H (1996) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg, 6. Aufl.

    Google Scholar 

  • Brown-Thomsen J (1973) Review of clinical trials with pipotiazine, pipotiazine undecylenate and pipotiazine palmitate. Acta Psychiatr Scand Suppl 241:119–138

    Article  PubMed  CAS  Google Scholar 

  • Carney MW (1973) Flupenthixol and the out-patient maintenance treatment of schizophrenia. Br J Psychiatry 122:371

    Article  PubMed  CAS  Google Scholar 

  • Carney MW, Sheffield BF (1973) The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol. Curr Med Res Opin 1:423–426

    Article  PubMed  CAS  Google Scholar 

  • Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11:440–452

    PubMed  Google Scholar 

  • Chowdhury ME, Chacon C (1980) Depot fluphenazine and flupenthixol in the treatment of stabilized schizophrenics. A double-blind comparative trial. Compr Psychiatry 21: 135–139

    Article  PubMed  CAS  Google Scholar 

  • Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DG, Waddington JL (1982) Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol 2:336–340

    Article  PubMed  CAS  Google Scholar 

  • Crow TJ (1985) The two-syndrome concept: origins and current status. Schizophr Bull 11: 471–486

    PubMed  CAS  Google Scholar 

  • Dencker SJ, Axelsson R (1996) Optimierung der Therapie mit Depotneuroleptika. CNS Drugs 6, 5:367–381

    Article  CAS  Google Scholar 

  • Eberhard G, Hellbom E (1986) Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatr Scand 74:255–262

    Article  PubMed  CAS  Google Scholar 

  • Ehmann TS, Delva NJ, Beninger RJ (1987) Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol. J Clin Psychopharmacol 7:173–175

    Article  PubMed  CAS  Google Scholar 

  • Eufe R, Wegener G (1979) Doppelblindvergleich von 2 Depotneuroleptika (Perphenazinönanthat und Flupentixoldecanoat) bei chronischer Schizophrenie. Nervenarzt 50: 534–539

    PubMed  CAS  Google Scholar 

  • Fenton WS, McGlashan TH (1991) Natural history of schizophrenia subtypes: Positive and negative symptoms and long-term course. Arch Gen Psychiatry 48:978–986

    Article  PubMed  CAS  Google Scholar 

  • Fiolet J (1981) Experience with depot neuroleptics in ambulatory practice. Acta Psychiatr Belg 81:182–188

    PubMed  CAS  Google Scholar 

  • Floru L, Heinrich K, Wittek F (1975) The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Long-term studies with fluspirilene and penfluridol and single-blind trial with fluphenazine-decanoate and flupenthixol-decanoate. Int Pharmacopsychiatry 10:230–239

    PubMed  CAS  Google Scholar 

  • Gaebel W (1990) Erfassung und Differenzierung schizophrener Minussymptomatik mit objektiven verhaltensanalytischen Methoden. In: Möller H-J et al (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin, S 79–90

    Chapter  Google Scholar 

  • Gerlach J, Kramp P, Kristjansen P, Lauritsen B, Lühdorf K, Munkvad I (1975) Peroral and parenteral administration of longacting neuroleptics: A double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. Acta Psychatr Scand 52:132

    Article  CAS  Google Scholar 

  • Gottfries CG (1971) Flupenthixol and trifluoperazine: a double-blind investigation in the treatment of schizophrenics. Br J Psychiatry 119:547–548

    Article  PubMed  CAS  Google Scholar 

  • Gottfries CG, Green L (1974) Flupenthixol decanoate in treatment of out-patients. Acta Psychiatr Scand Suppl 255:15–24

    Article  PubMed  CAS  Google Scholar 

  • Gross H, Kaltenbäck E (1965) Flupentixol, ein neues Neuroleptikum aus der Thioxanthenreihe (Klinische Erfahrungen bei einem psychiatrischen Krankengut). Acta Pychiatr Scand 41:42–56

    Article  Google Scholar 

  • Gross H, Kaltenbäck E (1972) Klinische Erfahrungen mit Flupentixoldecanoat (Fluanxol-Depot) bei chronischen Psychosen. Wien Klin Wochenschr 84:80–84

    PubMed  CAS  Google Scholar 

  • Gruber AJ, Cole JO (1991) Antidepressant effects of flupenthixol. Pharmacotherapy 11,6: 450–459

    PubMed  CAS  Google Scholar 

  • Haider I (1985) Flupenthixol decanoate (fluanxol depot) in the treatment of chronic schizophrenic patients. J Pak Med Assoc 35:286–289

    PubMed  CAS  Google Scholar 

  • Hamilton M, Card IR, Wallis GG, Mahmoud MR (1979) A comparative trial of the decanoates of flupenthixol and fluphenazine. Psychopharmacology Berl 64:225–229

    Article  PubMed  CAS  Google Scholar 

  • Haslam MT, Bromham BM, Schiff AA (1975) A comparative trial of fluphenazine decanoate and flupenthixol decanoate. Acta Psychiatr Scand 51:92–100

    Article  PubMed  CAS  Google Scholar 

  • Heinrich K (1967) Zur Bedeutung des postremissiven Erschöpfungssyndroms für die Rehabilitation Schizophrener. Nervenarzt 38:487–491

    PubMed  CAS  Google Scholar 

  • Helmchen H, Hippius H (1969) Pharmakogene Depression. In: Hippius H, Seibach H (Hrsg) Das depressive Syndrom. Urban & Schwarzenberg, München

    Google Scholar 

  • Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Wetzel H (1994) Amisulpride versus flupentixol in the treatment of schizophrenia with predominant positive symptomatology: A controlled double-blind study. Neuropsychopharmacology 10, 3 Suppl 2:31

    Google Scholar 

  • Hogarty GE, Goldberg SC, Scholer NR, Ulrich RF (1974) Drug and sociotherapy in the aftercare of schizophrenic patients: two year relapse rates. Arch Gen Psychiatry 31: 603–608

    Article  PubMed  CAS  Google Scholar 

  • Huang J, Yinliang S, Chenghua C, De Z, Huimin Z, Fusheng L, Liqun Y, Peng L, Suwen G, Hongxun W, Benshu X, Zhiwei S, Hu Z (1995) Untersuchung der therapeutischen Wirksamkeit von Flupenthixol bei der Behandlung von Patienten mit chronischer Schizophrenie vom Typ II. Chin J Neurol Psychiatry 28:269–272

    Google Scholar 

  • Jakobitsch A, Haug HJ, Greger J, Osterheide M, Pach J, Sprenger R, Tegeler J, Budde G (1996) Non-Compliance und fehlende Indikation zur Depotbehandlung als Ausschlußgründe für eine adäquate Rezidivprophylaxe. Psychiatr Prax 23:236–239

    PubMed  CAS  Google Scholar 

  • Johnson DA (1977) Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med 17:546–558

    PubMed  CAS  Google Scholar 

  • Johnson DA, Malik NA (1975) A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatr Scand 51:257–267

    PubMed  CAS  Google Scholar 

  • Johnson DA (1979) Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 135:524–530

    Article  PubMed  CAS  Google Scholar 

  • Johnson DA (1981) Depressions in schizophrenia: some observations on prevalence, etiology and treatment. Acta Psychiatr Scand Suppl 291:137–144

    Article  PubMed  CAS  Google Scholar 

  • Johnson DA (1981) Studies of depressive symptoms in schizophrenia. Br J Psychiatry 139: 89–101

    Article  PubMed  CAS  Google Scholar 

  • Johnson DA, Pasterski G, Ludlow JM, Street K, Taylor RD (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67:339–352

    Article  PubMed  CAS  Google Scholar 

  • Johnson DA, Ludlow JM, Street K, Taylor RD (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry 151:634–638

    Article  PubMed  CAS  Google Scholar 

  • Keefe RS, Mohs RC, Losonczy MF (1987) Characteristics of very poor outcome in schizophrenia. Am J Psychiatry 144:889–895

    PubMed  CAS  Google Scholar 

  • Kelly HB, Freeman HL, Banning B, Schiff AA (1977) Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. Int Pharmacopsychiatry 12:54–64

    PubMed  CAS  Google Scholar 

  • Kissling W, Möller H-J, Bäuml J, Dietzfelbinger T, Winter I (1990) Fluanxol Depot 10% versus Haloperidoldecanoat — Dosierung und Applikationsintervalle. Thioxanthene in der neuroleptischen Behandlung: 199–212

    Google Scholar 

  • Kistrup K, Gerlach J, Aaes JT, Larsen NE (1991) Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. Psychopharmacology Berl 105:42–48

    Article  PubMed  CAS  Google Scholar 

  • Knights A, Okasha MS, Salih MA, Hirsch SR (1979) Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. Br J Psychiatry 135:515–523

    Article  PubMed  CAS  Google Scholar 

  • Knights A, Hirsch SR (1981) „Revealed“depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38:806–811

    Article  PubMed  CAS  Google Scholar 

  • Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand Suppl 322:51–75

    Article  PubMed  CAS  Google Scholar 

  • Kong DS, Yeo SH (1985) Flupenthixol decanoate and fluphenazine decanoate in chronic schizophrenia. Singapore Med J 26:551–555

    PubMed  CAS  Google Scholar 

  • Malm U (1970) Intramuscular long-acting fluphenazine in the treatment of schizophrenia. Acta Psychiatr Scand 46:225–237

    Article  PubMed  CAS  Google Scholar 

  • Martyns-Yellowe I (1993) The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry. West Afr J Med 12:110–113

    PubMed  CAS  Google Scholar 

  • Martyns-Yellowe I (1994) The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West Afr J Med 13:200–203

    PubMed  CAS  Google Scholar 

  • Mayer-Walcher H (1974) Erfahrungen mit dem Neuroleptikum Fluanxol Depot. Therapiewoche 24:1437–1443

    Google Scholar 

  • McCreadie RG, Wiles D, Grant S, Crockett GT, Mahmood Z, Livingston MG, Watt JA, Greene JG, Kershaw PW, Todd NA et al (1989) The Scottish First Episode Schizophrenia Study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 80:597–602

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, Zureick J (1989) Negative symptoms in schizophrenia: a target for new drug development. In: Dahl SG, Gram LF (Hrsg) Clinical Pharmacology in Psychiatry. Springer, Berlin, S 365–376

    Google Scholar 

  • Merskey H (1986) Some observations on low dose flupenthixol for affective illness. Can J Psychiatry 31, 5:485

    PubMed  CAS  Google Scholar 

  • Möller H-J (1993) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3:1–11

    Article  PubMed  Google Scholar 

  • Möller H-J (1995) The negative component in schizophrenia. Acta Psychiatr Scand 91, Suppl 388:11–14

    Article  Google Scholar 

  • Ollerenshaw DP (1973) The classification of the functional psychoses. Br J Psychiatry 122: 517–530

    Article  PubMed  CAS  Google Scholar 

  • Pach J, Finkbeiner T, Greger J, Haug J, Osterheider M, Tegeler J. Positiv- und Negativsymptomatik bei chronisch schizophrenen Patienten unter Erhaltungstherapie mit Flupentixoldecanoat im 12-Monatsverlauf. Fortschr Neurol Psychiatr (in Druck)

    Google Scholar 

  • Parent M, Toussaint C (1983) Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica 3:354–364

    PubMed  CAS  Google Scholar 

  • Pinto R, Bannerjee A, Ghosh N (1979) A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatr Scand 60:313–322

    Article  PubMed  CAS  Google Scholar 

  • Rifkin A (1981) The risks of longterm neuroleptic treatment of schizophrenia: especially depression and akinesia. Acta Psychiatr Scand Suppl 291:129–134

    Article  PubMed  CAS  Google Scholar 

  • Robertson MM, Trimble MR (1981) Neuroleptics as antidepressants. Neuropharmacology 20:1335–1336

    Article  PubMed  CAS  Google Scholar 

  • Saikia JK, Jörgensen A (1983) Steady-state serum concentrations after cis(z)-flupenthixol decanoate in Viscoleo. Psychopharmacology 80:371–373

    Article  PubMed  CAS  Google Scholar 

  • Temkov I (1972) Home treatment of schizophrenics with long-acting major tranquilizers: Social and psychological assessment. Psychopharmacologia 26 Suppl: 108

    Google Scholar 

  • Trimble MR, Robertson MM (1983) Flupenthixol in depression. J Affect Disord 5:81–89

    Article  PubMed  CAS  Google Scholar 

  • Trueman HR, Valentine MG (1974) Flupenthixol decanoate in schizophrenia. Br J Psychiatry 124:58–59

    Article  PubMed  CAS  Google Scholar 

  • Vanelle JM (1996) Profil d’action des neuroleptiques dans les schizophrénies déficitaires. Encéphale 22 Spec No 2:33–39

    Google Scholar 

  • Vichaiya V (1980) Clinical trial of flupenthixol decanoate in chronic withdrawn schizophrenic patients. J Med Assoc Thai 63:205–209

    PubMed  CAS  Google Scholar 

  • Wistedt B (1981) A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 64:65–84

    Article  PubMed  CAS  Google Scholar 

  • Wistedt B, Jorgensen A, Wiles D (1982) A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology Berl 78:301–304

    Article  PubMed  CAS  Google Scholar 

  • Wistedt B, Ranta J (1983) Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatr Scand 67:378–388

    Article  PubMed  CAS  Google Scholar 

  • Wistedt B, Palmstierna T (1983) Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. J Clin Psychiatry 44:369–371

    PubMed  CAS  Google Scholar 

  • Woggon B, Angst J, Margoses N (1975) Gegenwärtiger Stand der neuroleptischen Langzeitbehandlung der Schizophrenie. Nervenarzt 46:611–616

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Gartenmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Gaese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Soyka
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Geschäftsbereich Pharma Medizin/ZNS, Bayer Vital GmbH & Co. KG, Geb.: D 162, 51368, Leverkusen, Deutschland

    T. Glaser

  2. Psychiatrische Klinik und Poliklinik mit Konsiliardienst Großhadern, Klinikum Innenstadt, Nußbaumstraße 7, 80336, München, Deutschland

    M. Soyka

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Gartenmaier, A., Gaese, F., Soyka, M. (1998). Effizienz von Flupentixol bei schizophrenen Erkrankungen. In: Glaser, T., Soyka, M. (eds) Flupentixol — Typisches oder atypisches Wirkspektrum?. Steinkopff. https://doi.org/10.1007/978-3-642-93700-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93700-2_4

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1125-5

  • Online ISBN: 978-3-642-93700-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation